

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2015 Army **Date:** March 2014

Appropriation/Budget Activity 2040: <i>Research, Development, Test & Evaluation, Army</i> / BA 3: <i>Advanced Technology Development (ATD)</i>					R-1 Program Element (Number/Name) PE 0603105A / <i>MILITARY HIV RESEARCH</i>							
COST (\$ in Millions)	Prior Years	FY 2013	FY 2014	FY 2015 Base	FY 2015 OCO #	FY 2015 Total	FY 2016	FY 2017	FY 2018	FY 2019	Cost To Complete	Total Cost
Total Program Element	-	20.920	-	-	-	-	-	-	-	-	-	-
H29: <i>Med Protect Agnst Hiv</i>	-	6.228	-	-	-	-	-	-	-	-	-	-
T16: <i>MILITARY HIV INITIATIVES CA</i>	-	14.692	-	-	-	-	-	-	-	-	-	-

The FY 2015 OCO Request will be submitted at a later date.

Note

FY13 adjustments attributed to increase for Congressional Add funding (+16.0 million); SBIR/STTR transfers (-188 thousand); and Sequestration reductions (-1.846 million)

A. Mission Description and Budget Item Justification

This PE matures and demonstrates advanced technology of candidate human immunodeficiency virus (HIV) vaccines, prepares and conducts human clinical studies to assess safety and effectiveness of candidate HIV vaccines, conducts research to control HIV infection in military environments, protects the military blood supply from HIV, and protects military personnel from risks associated with the HIV infection. All HIV technology development activities are conducted in compliance with FDA regulations. FDA requires thorough testing in animal models (preclinical testing) to ensure safety and effectiveness prior to approving controlled clinical evaluation of drugs, vaccines, and medical devices in humans. Normally, clinical trials are conducted in three phases to prove safety and effectiveness of the drug, vaccine, and device for the targeted disease or condition. An increasing number of test subjects are used in each subsequent phase. All results are submitted to FDA for evaluation to ultimately obtain approval (licensure) for routine medical use. This program is jointly managed through an Interagency Agreement by the U.S. Army Medical Research and Materiel Command (USAMRMC), the National Institutes of Health, and the National Institute of Allergy and Infectious Diseases (NIAID).

This project contains no duplication with any effort within the Military Departments or other government organizations.

Work is fully coordinated with work funded in program element PE 0602787A, project 873 (HIV Exploratory Research).

The cited work is consistent with the Assistant Secretary of Defense, Research and Engineering Science and Technology, focus areas and the Army Modernization Strategy.

Work in this PE is performed by WRAIR, Silver Spring, MD, and its overseas laboratories, and NMRC, Silver Spring, MD, and its overseas laboratories. The Henry M. Jackson Foundation, located in Bethesda, MD, provides support for FDA testing and other research under cooperative agreement.

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2015 Army				Date: March 2014	
Appropriation/Budget Activity		R-1 Program Element (Number/Name)			
2040: Research, Development, Test & Evaluation, Army / BA 3: Advanced Technology Development (ATD)		PE 0603105A / MILITARY HIV RESEARCH			
B. Program Change Summary (\$ in Millions)	FY 2013	FY 2014	FY 2015 Base	FY 2015 OCO	FY 2015 Total
Previous President's Budget	6.984	-	-	-	-
Current President's Budget	20.920	-	-	-	-
Total Adjustments	13.936	-	-	-	-
• Congressional General Reductions	-0.030	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	16.000	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-0.188	-			
• Sequestration	-1.846	-	-	-	-

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Army										Date: March 2014		
Appropriation/Budget Activity 2040 / 3					R-1 Program Element (Number/Name) PE 0603105A / MILITARY HIV RESEARCH				Project (Number/Name) H29 / Med Protect Agnst Hiv			
COST (\$ in Millions)	Prior Years	FY 2013	FY 2014	FY 2015 Base	FY 2015 OCO #	FY 2015 Total	FY 2016	FY 2017	FY 2018	FY 2019	Cost To Complete	Total Cost
H29: Med Protect Agnst Hiv	-	6.228	-	-	-	-	-	-	-	-	-	-
# The FY 2015 OCO Request will be submitted at a later date.												
Note Starting in FY 14, resources for this program were realigned from RDT&E,Army to Defense Health Program												
A. Mission Description and Budget Item Justification												
This project funds research to develop candidate HIV vaccines, to assess their safety and effectiveness in human subjects, and to protect the military personnel from risks associated with HIV infection. In addition, it is designed to find ways to protect the blood supply from contamination with HIV virus. All HIV technology development is conducted in compliance with U.S. Food and Drug Administration (FDA) regulations. Evaluations in human subjects are conducted to demonstrate safety and effectiveness of candidate vaccines, as required by FDA regulation. Studies are conducted stepwise: first, to prove safety; second, to demonstrate the desired effectiveness of the drug, vaccine, or device for the targeted disease or condition in a small study; and third, to demonstrate effectiveness in large, diverse human population trials. All results are submitted to the FDA for evaluation to ultimately obtain approval (licensure) for medical use. This project supports studies for effectiveness testing on small study groups after which they transition to the next phase of development for completion of effectiveness testing in larger populations.												
This program is jointly managed through an Interagency Agreement by USAMRMC and NIAID. This project contains no duplication with any effort within the Military Departments or other government organizations.												
Work is fully coordinated with work funded in program element PE 0602787A, project 873 (HIV Exploratory Research), and are further matured under PE 0603807A, project 811.												
The cited work is consistent with the Assistant Secretary of Defense, Research and Engineering Science and Technology, focus areas and the Army Modernization Strategy.												
Work in this PE is performed by the Walter Reed Army Institute of Research, Silver Spring, MD, and its overseas laboratories. Significant work is conducted under a cooperative agreement with the Henry M. Jackson Foundation, Bethesda, MD.												
B. Accomplishments/Planned Programs (\$ in Millions)									FY 2013	FY 2014	FY 2015	
Title: HIV Program									6.228	-	-	
Description: This project funds research to develop candidate HIV vaccines, assess their safety and effectiveness in evaluations with human subjects, and protect military personnel from risks associated with HIV infection.												
FY 2013 Accomplishments:												

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Army		Date: March 2014	
Appropriation/Budget Activity 2040 / 3	R-1 Program Element (Number/Name) PE 0603105A / <i>MILITARY HIV RESEARCH</i>	Project (Number/Name) H29 / <i>Med Protect Agnst Hiv</i>	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2013	FY 2014
Conducted initial safety studies in humans with candidate vaccines consisting of multiple subtypes in clinical trial sites in Asia and Africa and conducted studies in humans to assess performance and ability of HIV vaccine candidates to provoke an immune response that can protect against HIV.			
Accomplishments/Planned Programs Subtotals		6.228	-
C. Other Program Funding Summary (\$ in Millions) N/A			
Remarks			
D. Acquisition Strategy N/A			
E. Performance Metrics N/A			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2015 Army										Date: March 2014																						
Appropriation/Budget Activity 2040 / 3					R-1 Program Element (Number/Name) PE 0603105A / <i>MILITARY HIV RESEARCH</i>				Project (Number/Name) T16 / <i>MILITARY HIV INITIATIVES CA</i>																							
COST (\$ in Millions)	Prior Years	FY 2013	FY 2014	FY 2015 Base	FY 2015 OCO #	FY 2015 Total	FY 2016	FY 2017	FY 2018	FY 2019	Cost To Complete	Total Cost																				
T16: <i>MILITARY HIV INITIATIVES CA</i>	-	14.692	-	-	-	-	-	-	-	-	-	-																				
# The FY 2015 OCO Request will be submitted at a later date. A. Mission Description and Budget Item Justification Congressional Interest Item projects for HIV Research. B. Accomplishments/Planned Programs (\$ in Millions) <table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th></th> <th>FY 2013</th> <th>FY 2014</th> <th>FY 2015</th> </tr> </thead> <tbody> <tr> <td>Title: HIV Research</td> <td align="right">14.692</td> <td align="center">-</td> <td align="center">-</td> </tr> <tr> <td>Description: This is a Congressional Interest Item.</td> <td></td> <td></td> <td></td> </tr> <tr> <td>FY 2013 Accomplishments: HIV Research</td> <td></td> <td></td> <td></td> </tr> <tr> <td align="right">Accomplishments/Planned Programs Subtotals</td> <td align="right">14.692</td> <td align="center">-</td> <td align="center">-</td> </tr> </tbody> </table> C. Other Program Funding Summary (\$ in Millions) N/A Remarks D. Acquisition Strategy N/A E. Performance Metrics N/A														FY 2013	FY 2014	FY 2015	Title: HIV Research	14.692	-	-	Description: This is a Congressional Interest Item.				FY 2013 Accomplishments: HIV Research				Accomplishments/Planned Programs Subtotals	14.692	-	-
	FY 2013	FY 2014	FY 2015																													
Title: HIV Research	14.692	-	-																													
Description: This is a Congressional Interest Item.																																
FY 2013 Accomplishments: HIV Research																																
Accomplishments/Planned Programs Subtotals	14.692	-	-																													